BRISBANE, Calif.–( BUSINESS WIRE )–CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ “a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers” today announced, on September 12 2024, CareDx (NASDAQ: ) granted an option to purchase 100,651 shares of CareDx common stock (Kennedy Inducement Options) and 70,101 restricted stock units (Kennedy Inducement RSUs) to Keith S. Kennedy, CareDx’s newly appointed Chief Operating Officer, and an option to purchase 75,488 shares of CareDx common stock (Meng Inducement Options and, together with Kennedy Inducement Options, Inducement Options) and 52,576 restricted stock units (Meng Inducement RSUs and, together with Kennedy Inducement RSUs, Inducement RSUs) to Jessica Meng, Chief Commercial Officer of CareDx The newly appointed Induction Option and Induction RSU were approved by the Compensation and Human Capital Committee of the CareDx board of directors on September 6, 2024 and are incentives for Mr. Kennedy and Ms. Meng’s employment at CareDx in accordance with Nasdaq Listing Rule 5635 (c)(4).
The Inducement Option has an exercise price of $29.43 and will vest over four years, with 25% of the total number of shares subject to the Inducement Option on September 12, 2025, the one-year anniversary of the commencement date of Kennedy’s and Meng’s employment with CareDx, and 1/48 of the total number shares that are subject to Option Inducement vesting at the end of each calendar month thereafter, subject in each case to Kennedy and Meng who continue to serve with CareDx on each vesting date. The Inducement RSUs will vest in four equal annual installments beginning on September 12, 2025, the one-year anniversary of Kennedy’s and Meng’s commencement of employment with CareDx, subject in each case to Kennedy’s and Meng’s continued service with CareDx on each vesting date.
CareDx provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About CareDx “ The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers digital health testing services, products and solutions throughout the patient journey before and after transplant and is the leading provider of genomics-based information for transplant patients. For more information, visit www.caredx.com.
Forward Looking Statements
This press release contains forward-looking statements relating to CareDx, Inc., including statements regarding equity grants. These forward-looking statements are based on information currently available to CareDx and current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including the general economy. and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 that CareDx filed with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the fiscal quarter ended 31 March 2024 that CareDx filed with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 that CareDx filed with the SEC on July 31, 2024, and other reports that CareDx has filed with the SEC. Any of these could cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or promise to update or revise such forward-looking statements.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20240913316306/en/
CareDx, Inc.
Media Relations
Anna Czene
818-731-2203
aczene@caredx.com
Investor Relations
Greg Chodaczek
investors@caredx.com
Source: CareDx, Inc.
